Real World Data In Europe Show Majority Of Diabetic Macular

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Real World Data In Europe Show Majority Of Diabetic Macular Edema Patients Gain Or Maintain Vision With Iluvien® At 12 Months

Despite other prior treatments, improvements in visual acuity and retinal thickness were seen in the majority of patients

Efficacy and safety data are comparable with Phase III FAME clinical trials

ATLANTA, May 23, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences Limited, the European subsidiary of Alimera Sciences, Inc. (NASDAQ: ALIM ) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced the availability of real world data showing that the majority of diabetic macular edema (DME) patients who received ILUVIEN ® (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) in routine clinical practice gained or maintained vision at 12 months.

In contrast with the pivotal clinical trials known as the FAME studies, where all patients had prior laser therapy and few had received anti-vascular endothelial growth factor (anti-VEGF) therapies, in the ILUVIEN Registry Safety Study at least two thirds are known to have received prior anti-VEGF injections. Despite these prior treatments, patient vision outcomes, intraocular pressure (IOP) increases and other side effects were comparable to the FAME results.

"It is exciting to see that the ILUVIEN real world data in Europe in patients that are primarily refractory to anti-VEGF therapy mirror FAME results several years later after the emergence of changing treatment patterns with anti-VEGF therapy," said Dan Myers, Alimera's chief executive officer.

Professor Usha Chakravarthy from Queen’s University Belfast, principal investigator of this post authorization study, said: “In these real world studies, patients were switched to ILUVIEN when clinicians had determined that despite other treatments there was vision decline and worsening appearance of the macula. Following the switch there were improvements in visual acuity and retinal morphology in the majority of patients showing that ILUVIEN is an important addition to our therapeutic armamentarium.”

The data were revealed for the first time at the Royal College of Ophthalmologists (RCOpth) Annual Congress in Birmingham, England today. The two real world data sources consist of a European registry study and a patient review audit from the United Kingdom (U.K.).

  • The ILUVIEN ® Registry Safety Study is a post authorization safety study that Alimera is required to perform in Europe. Interim data presented at the RCOpth Congress is from 328 eyes (292 patients) from 25 centers in the U.K., 10 in Germany and one in Portugal. This study collects primary data on safety and some visual acuity, but no data from optical coherence tomography (OCT).
  • The ongoing “Medisoft” audit is a post hoc chart review that has gathered data on 290 eyes (258 patients) from the Medisoft ® EMR data systems used in 13 U.K. centers. Medisoft collects retrospective safety data and best collected vision and some data from OCT.

Vision improved in 58.0% of Registry Safety Study patients at 6 months and 61.0% at 12 months, which is comparable with the FAME trials. Mean visual acuity increased from 50.9 letters at baseline to 55.7 letters at six and twelve months, with 15.9% of patients gaining ≥15 letters at 6 months and 20.8% of patients gaining ≥15 letters at 12 months. 27.0% of patients at 6 months and 34.0% at 12 months regained vision that was better than 20/40, which is often a minimum requirement for driving.

In this study, unlike FAME, some patients were on IOP lowering medications prior to ILUVIEN use. Interim results from this European study show that 81.6% of patients required no new or additional IOP-lowering medication, 9.9% had an IOP increase of ≥10mm Hg and 8.2% had an IOP elevation of above 30mm Hg. Regarding cataract formation, among the 51 phakic (natural lens) eyes treated in the study, 14 (27.4%) underwent cataract surgery for an existing cataract concurrent with their ILUVIEN injection, 5 (9.8%) developed a cataract on ILUVIEN, and 10 (19.6%) underwent cataract surgery for existing or new cataracts.

In the interim Medisoft audit, visual acuity data was not captured because it was a post hoc audit and there was variability in the assessment procedures across clinical practices. The audit data show that 85.2% of patients required no new or additional IOP-lowering medication, which is similar to the registry study results. In the 14.8% of patients who did require new or additional IOP management, IOP changes were consistent with the FAME trials and well managed. In the small number of phakic patients included in the Medisoft audit, cataract progression was comparable to that seen in phakic patients in the FAME trials.

The mean change in foveal thickness (reduction in edema) at the last observation was -148.5 microns (p<0.001).

Miss Clare Bailey from Bristol Eye Hospital, who leads the Medisoft audit, added, “Since the ILUVIEN Phase III registration clinical trials were conducted in 2005-2011, the management of patients with DME has changed significantly with the widespread use of anti-VEGF agents. These data demonstrate that in the real world, ILUVIEN can improve or preserve vision with a side effect profile similar to that seen in the Phase III FAME studies in the majority of patients with DME, even when previous anti-VEGF treatments have failed to deliver a sufficient response and we are very pleased to have it as a treatment option for our patients.”

About ILUVIEN

www.ILUVIEN.com .

ILUVIEN'S U.S. Indication

ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant approved in the U.S. to treat diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Each ILUVIEN implant is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for 36 months.

ILUVIEN'S E.U. Indication

ILUVIEN is indicated for the treatment of vision impairment associated with chronic diabetic macular oedema, considered insufficiently responsive to available therapies.

The ILUVIEN ® Registry Safety Study or IRISS is a requirement as part of the approval process in the EEA, where Alimera committed to conduct a five-year, post-authorization, open label registry study in 800 patients treated with ILUVIEN. Through March 31, 2016, Alimera has enrolled over 324 patients.

The “Medisoft” study is a 13 center, real world data UK study which gathers data from the Medisoft electronic medical records data systems used in the study centers. This was presented as a poster at the Royal College of Ophthalmologists’ Annual Congress 2016 entitled “UK multi-centre, retrospective audit of electronic patient records to assess the real-world intraocular pressure events following treatment with ILUVIEN® 190 micrograms intravitreal implant for up to 24 months.” This study is ongoing and latest interim data was extracted in February 2016.

About Diabetic Macular Edema (DME)

DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME. The onset of DME is painless and may go unreported by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found that over a 10-year period approximately 19% of people with diabetes included in the study were diagnosed with DME. All people with type 1 or type 2 diabetes are at risk of developing DME.

About Alimera Sciences, Inc.

www.alimerasciences.com

Alimera Sciences (NASDAQ: ALIM ), founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in Alimera’s product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit  www.alimerasciences.com .

For press inquiries: Katie Brazel for Alimera Sciences 404-317-8361 kbrazel@bellsouth.net For investor inquiries: CG Capital for Alimera Sciences 877-889-1972 investorrelations@cg.capital

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hone Health’s $228M Bet on Data-Led Longevity Care

Updated Category News Views 191

Longevity medicine just got a very large check and an even larger assignment. Hone Health says it has raised $228 million to push physician-led care beyond its roots in hormone optimization, and the split of that financing matters more than the celebrity names attached to it. Only $28 million is described as Series A equity; the other $200 million comes as growth...

Continue Reading
Hanmi Compressor Tests Vietnam Before Wider Expansion

Updated Category News Views 125

Compressed air is the sort of factory necessity nobody brags about until it fails, and that is precisely why Hanmi Compressor’s Vietnam plan deserves a sober look. The Daegu-based specialist is not arriving with a grand export victory lap. It is still building the front door: a website, a promotional video, and a process for finding Vietnamese manufacturers and...

Continue Reading
PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 95

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
Airtel Money Upgrade Raises the Stakes in East Africa

Updated Category News Views 77

Mobile money lives or dies in the irritating little moments: a transfer that hangs, a menu that makes people punch five buttons too many, a merchant payment that simply will not clear. Airtel Money is attacking that friction in Malawi and Tanzania with an enhanced platform from Comviva, and this is more consequential than the usual software-refresh chest thumping. In...

Continue Reading
Litmus Gets $475 Million as Music Rights Mature Further

Updated Category News Views 107

Music royalties just got another serious pile of institutional money, and Litmus is holding the shovel. The company announced roughly $475 million of new capital commitments from Carlyle and investment funds managed by KKR, a notable vote of confidence in a platform that did not even exist before 2022. This is not some celebrity vanity vehicle buying a famous chorus and...

Continue Reading
Wallstreet Sand Hands Its Massive Permian Plant to Wilbanks

Updated Category News Views 171

A sand plant can brag about acreage and horsepower all day, but frac crews remember who kept material arriving when a completion schedule got ugly. That is the real backdrop to PI Holdings and Wallstreet Sand Co. naming Blaine Wilbanks president of both businesses on November 18, 2026. This is not a ceremonial chair swap. Wallstreet has built an enormous Permian sand...

Continue Reading
Century Complete Tests Conway Demand Near Myrtle Beach

Updated Category News Views 72

Ninety-four lots in Conway may not move Wall Street by themselves, but they can say plenty about the kind of buyer Century Communities is chasing. Century Complete is opening its model at Cates Bay Crossing on Nov. 21, 2026, with single-family homes starting in the $260s. In a housing market where affordability gets talked to death and rarely delivered cleanly, that...

Continue Reading
Peptide Labels Cannot Substitute for Clinical Care

Updated Category News Views 91

A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...

Continue Reading
Star Catcher Powers a Public-Interest Space Bet Ahead

Updated Category News Views 23

A satellite’s battery budget is a rotten place for humanitarian priorities to die. Common Space and Star Catcher are trying to remove that bottleneck through a partnership that is easy to like on principle and still deserves a clear-eyed look on execution. Common Space, a nonprofit developing an independent, community-governed high-resolution satellite constellation,...

Continue Reading
Sysco's Northern California Labor Deal Gets Bigger

Updated Category News Views 20

One hundred forty-four drivers may not rattle a giant food distributor by themselves, but labor agreements have a habit of growing legs. Sysco's Northern California and Nevada regional contract has added members from Teamsters Locals 386 and 431, bringing its coverage above 1,100 workers. For investors watching Sysco, this is less about one afternoon's headline and more...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Promising Industrials Stocks: AVAV, GMS, VRRM Insights

Updated Category News Views 190

Identifying Opportunities in the Industrials Sector In today's market, identifying oversold stocks in the industrials sector presents a golden opportunity for investors seeking undervalued assets. An oversold stock usually indicates that its price has dropped significantly, creating potential for future upward movement. Understanding the RSI Indicator The Relative...

Continue Reading
Florida Cancer Specialists Innovates Care with Navigation Program

Updated Category News Views 252

Florida Cancer Specialists Revolutionizes Oncology Navigation Florida Cancer Specialists & Research Institute, LLC (FCS) recently unveiled an intriguing case study that illustrates the profound impact of their patient navigation program. This initiative is structured under the Principal Illness Navigation (PIN) billing codes introduced by the Centers for Medicare &...

Continue Reading
Celebrating Creativity: ASCAP Composers' Choice Awards 2025

Updated Category News Views 267

ASCAP Honors Top Screen Composers for 2025 The American Society of Composers, Authors and Publishers (ASCAP) has recognized the incredible talent of top screen composers at the highly anticipated ASCAP Composers' Choice Awards for 2025. This event highlights the artists whose musical creations bring depth and emotion to films, TV series, and video games. The awards shine...

Continue Reading
Innovative Features of Catalogic's DPX vPlus Unveiled

Updated Category News Views 105

Enhancing Data Protection with DPX vPlus 7.0 Catalogic Software, a reputable provider of secure data protection solutions with over 25 years of experience, has recently launched an impressive upgrade to its enterprise data protection software: DPX vPlus 7.0. This new version is designed to meet the evolving needs of modern enterprise environments, offering significant...

Continue Reading
Legal Action Reminders for Investors in CAE, Inc.

Updated Category News Views 99

Investor Alert: Class Action Lawsuit Against CAE, Inc. ClaimsFiler is notifying investors about a significant legal case involving CAE, Inc. (NYSE: CAE). If you've experienced losses exceeding $100,000 from your investment in CAE, it's important to take action quickly to safeguard your rights. Overview of the Class Action Lawsuit This lawsuit claims that CAE and certain...

Continue Reading